Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of Non-estrogenic Pollen Extract PCC-100 on Hot Flushes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03684096
Recruitment Status : Recruiting
First Posted : September 25, 2018
Last Update Posted : December 31, 2018
Sponsor:
Information provided by (Responsible Party):
Vrouwenkliniek, University Hospital, Ghent

Brief Summary:
Many postmenopausal women have vasomotor symptoms during adjuvant hormonal treatment for breast cancer. PCC-100 is a pollen extract used for alleviation of postmenopausal symptoms. In a randomised, double blinded study pollen extract PCC-100 will be used to treat vasomotor complaints in postmenopausal women under adjuvant hormonal treatment and also in menopausal women without a history of breast cancer.

Condition or disease Intervention/treatment Phase
Breast Cancer Hot Flashes Postmenopausal Symptoms Dietary Supplement: non-estrogenic pollen extract PCC-100 Other: placebo Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 300 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: The Effect of the Non-estrogenic Pollen Extract PCC-100 on Hot Flushes During Adjuvant Hormonal Treatment for Breast Cancer in Postmenopausal Women and in Menopausal Women Without a History of Breast Cancer
Actual Study Start Date : October 15, 2018
Estimated Primary Completion Date : August 1, 2021
Estimated Study Completion Date : January 1, 2022

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Menopause
Drug Information available for: Bee pollen

Arm Intervention/treatment
Active Comparator: non-estrogenic pollen extract PCC-100
After randomisation patients will be devided in the group who will take the non-estrogenic pollen extract PCC-100 or the group who will receive placebo. The patients will take the drug or placebo for 12 weeks. During these 12 weeks the patients need to register the number and severity of the hot flashes. The patient will have 2 study visits during those 12 weeks.
Dietary Supplement: non-estrogenic pollen extract PCC-100
non-estrogenic pollen extract PCC-100

Placebo Comparator: placebo
After randomisation patients will be devided in the group who will take the non-estrogenic pollen extract PCC-100 or the group who will receive placebo. The patients will take the drug or placebo for 12 weeks. During these 12 weeks the patients need to register the number and severity of the hot flashes. The patient will have 2 study visits during those 12 weeks.
Other: placebo
placebo -non-estrogenic pollen extract PCC-100




Primary Outcome Measures :
  1. Daily frequency of hot flashes [ Time Frame: 12 weeks ]
    Daily frequency of hot flashes as mentioned in the daily diary the subjects need to complete during 12 weeks. The patient indicate in the diary the number, intensity (mild, moderate, severe) of hotflashes every day


Secondary Outcome Measures :
  1. Menopause symptoms [ Time Frame: 6-8 weeks after randomisation and 12 weeks after randomisation ]
    Symptoms related to menopause will be asked to the patients by using the Menopause Rating Scale (MRS), this is a questionnaire with 11 questions about menopause and you can scale every question from 1 (no complaints) to 4 (severe).

  2. Menopause symptoms [ Time Frame: 6-8 weeks after randomisation and 12 weeks after randomisation ]
    Symptoms related to menopause will be asked to the patients by using the Green Climacteric Scale. This is a questionnaire of 21 questions about menopause. Every question can be scored from no complaints to very severe.

  3. Influence of hot flashes on daily life [ Time Frame: 6-8 weeks after randomisation and 12 weeks after randomisation ]
    Influence of hot flashes on daily life will be asked by using a questionnaire: Hot-Flash Related daily interference scale. This 10-item scale measures a woman's perceptions of the degree to which hot flashes interfere with nine daily life activities; the tenth item measures interference with overall quality of life



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   50 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Gender Based Eligibility:   Yes
Gender Eligibility Description:   only women will be recruited
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Postmenopausal women, between 50 and 65 years old (extremes included) at the time of signing the informed consent form;
  • spontaneous amenorrhea for at least 6 consecutive months in combination with a hormonal diagnosis of being postmenopausal (FSH > 40 mU/ml and E2 < 20 pg/ml. In subjects using Tamoxifen, only E2 needs to be determined) or spontaneous amenorrhea for at least 12 consecutive months or having had a bilateral oophorectomy at least 6 weeks prior to screening (with or without hysterectomy);
  • a history of breast cancer, whatever the received treatment, and currently taking aromatase inhibitors or Tamoxifen since at least 4 weeks. This criterion is not applicable to the 100 subjects entering the study without a history of breast cancer;
  • a minimum of 49 moderate to severe hot flushes or night sweats during 7 consecutive 24-h periods;
  • a body mass index [BMI] between 18.0 and 35.0 kg/m2, inclusive;
  • proven normal glycaemia and normal thyroid function as evidenced in a recent serum analysis (in the last year) performed by the General Practitioner or gynaecologist;
  • The subject is able to understand and comply with the protocol requirements, instructions, and protocol-stated restrictions.

Exclusion Criteria:

  • Recently, an abnormal cervical Pap smear that requires surgery within 6 months;
  • acute or chronic thromboembolic disease, liver disease and/or renal impairment;
  • uncontrolled diabetes mellitus;
  • uncontrolled hypertension;
  • uncontrolled thyroid disorders;
  • the subject has a history of a major depression or post-traumatic stress disorder [PTSD] within 2 years of screening. Women taking antidepressants can be included after a wash out period of 6 weeks;
  • use of (non-)hormonal treatments to reduce hot flushes, unless a wash-out period is respected;
  • a history or presence of allergy or intolerance to the investigational product or any component of the investigational product or drugs in this class. Or history of drug or other allergy that, in the opinion of the investigator contraindicates subject participation;
  • a history of alcohol or substance abuse or dependence in the 12 months before screening as determined by the investigator;
  • judged by the investigator to be unsuitable for any reason.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03684096


Contacts
Layout table for location contacts
Contact: Eline Meireson, Msc 0032 9 332 78 17 eline.meireson@uzgent.be

Locations
Layout table for location information
Belgium
Ghent University Hospital Recruiting
Gent, East Flanders, Belgium, 9000
Contact: Eline Meireson    0032 9 332 78 17    eline.meireson@uzgent.be   
Sponsors and Collaborators
University Hospital, Ghent

Layout table for additonal information
Responsible Party: Vrouwenkliniek, professor, University Hospital, Ghent
ClinicalTrials.gov Identifier: NCT03684096     History of Changes
Other Study ID Numbers: EC/2017/1261
First Posted: September 25, 2018    Key Record Dates
Last Update Posted: December 31, 2018
Last Verified: December 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Hot Flashes
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Signs and Symptoms